Psilocybin vs Ketamine for Alcohol Use Disorder (Psi vs Ket)

This double-blind, randomised, active-comparator trial (n=80) will study the effects of psilocybin (30mg) versus ketamine (52.5mg/70kg) for alcohol use disorder (AUD).

Conducted by the University of Iowa and led by Dr Peggy C Nopoulos, the study will involve two arms: Arm 1 (n=40) receiving individual psychotherapy sessions plus a 30 mg dose of oral psilocybin, and Arm 2 (n=40) receiving individual psychotherapy sessions plus a 0.75 mg/kg dose of intramuscular ketamine.

The primary outcome measure is the Timeline Follow-Back for Alcohol to assess changes in alcohol use over 16 weeks. Secondary measures include T1rho for biological brain changes, resting state fMRI for global functional connectivity, and EEG-signal complexity.

The study, scheduled to start in June 2024 and complete by June 2027, aims to provide insights into the efficacy and safety of these psychedelic interventions for AUD.

Topic Alcohol Use Disorder Addiction
Compound Psilocybin Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Iowa
The Niciu Lab at the University of Iowa is interested in the therapeutic effects of ketamine.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.